Skip navigation


What is it?

L-arginine is a chemical building block called “an amino acid.” It is obtained from the diet and is necessary for the body to make proteins. L-arginine is found in red meat, poultry, fish, and dairy products. It can also be made in a laboratory and used as medicine.

L-arginine is used for heart and blood vessel conditions including congestive heart failure (CHF), chest pain, high blood pressure, and coronary artery disease. L-arginine is also used for recurrent pain in the legs due to blocked arteries (intermittent claudication), decreased mental capacity in the elderly (senile dementia), erectile dysfunction (ED), and male infertility.

Some people use L-arginine for preventing the common cold, improving kidney function after a kidney transplant, high blood pressure during pregnancy (pre-eclampsia), improving athletic performance, boosting the immune system, and preventing inflammation of the digestive tract in premature infants.

L-arginine is used in combination with a number of over-the-counter and prescription medications for various conditions. For example, L-arginine is used along with ibuprofen for migraine headaches; with conventional chemotherapy drugs for treating breast cancer; with other amino acids for treating weight loss in people with AIDS; and with fish oil and other supplements for reducing infections, improving wound healing, and shortening recovery time after surgery.

Some people apply L-arginine to the skin to speed wound healing and for increasing blood flow to cold hands and feet, especially in people with diabetes. It is also used as a cream for sexual problems in both men and women.

How effective is it?

Natural Medicines Comprehensive Database rates effectiveness based on scientific evidence according to the following scale: Effective, Likely Effective, Possibly Effective, Possibly Ineffective, Likely Ineffective, Ineffective, and Insufficient Evidence to Rate.

The effectiveness ratings for L-ARGININE are as follows:

Possibly effective for...

  • Chest pain (angina). Taking L-arginine seems to decrease symptoms and improve exercise tolerance and quality of life in people with angina. However, L-arginine does not seem to improve the disease itself.
  • Erectile dysfunction (ED). Taking 5 grams of L-arginine by mouth daily seems to improve sexual function in men with ED. Taking lower doses might not be effective. However, there is some early evidence that adding 40 mg of Pycnogenol three times daily might improve the effectiveness of low-dose L-arginine for ED.
  • High blood pressure. There is early evidence that taking L-arginine by mouth can reduce blood pressure in healthy people, people with high blood pressure, and people with slightly high blood pressure with or without diabetes.
  • Inflammation of the digestive tract in premature infants. Adding L-arginine to formula seems to prevent inflammation of the digestive tract in premature infants.
  • Nitrate tolerance. Taking 700 mg of L-arginine four times daily seems to prevent nitrate tolerance in people taking nitroglycerin for chest pain (angina pectoris).
  • Leg pain associated with poor blood flow (peripheral arterial disease). Research suggests that taking L-arginine by mouth or intravenously (by IV) for up to 8 weeks increases blood flow in people with peripheral arterial disease. However, long-term use (up to 6 months) does not improve walking speed or distance in people with peripheral arterial disease.
  • Improving recovery after surgery. Taking L-arginine with ribonucleic acid (RNA) and eicosapentaenoic acid (EPA) before surgery or afterwards seems to help reduce the recovery time, reduce the number of infections, and improve wound healing after surgery.
  • High blood pressure during pregnancy (pre-eclampsia). Although there are inconsistent results about the effects of L-arginine on pre-eclampsia, most research suggests that it can reduce blood pressure in women with this condition.

Possibly ineffective for...

  • Kidney disease. Most early research suggests that taking L-arginine, either by mouth for up to 6 months or intravenously (by IV) for a short time, does not improve kidney function in people with kidney failure or kidney disease.However, taking 1.3 grams of L-arginine by mouth daily seems to improve kidney function and reverse anemia in elderly people with kidney disease-associated anemia.
  • Heart attack. Taking L-arginine does not seem to help prevent a heart attack. It also does not seem to be beneficial for treating a heart attack after it has occurred. In fact, there is concern that L-arginine might be harmful for people after a recent heart attack. Do not take L-arginine if you have had a recent heart attack.
  • Wound healing. Taking L-arginine does not seem to improve wound healing.

Insufficient evidence to rate effectiveness for...

  • AIDS-related wasting. Taking L-arginine by mouth, together with hydroxymethylbutyrate (HMB) and glutamine, for 8 weeks seems to increase body weight and improve immune function in people with HIV/AIDS. However, taking 7.4 grams of L-arginine by mouth daily, together with omega-3 faty acids and a balanced nutritional supplement, for 6 months does not improve body weight or fat mass, energy intake, or immune function in people who are HIV-positive.
  • Altitude sickness. Early research suggests that L-arginine does not reduce altitude sickness.
  • Anal fissures. There is inconsistent evidence about that effects of L-arginine for treating anal fissures. Applying L-arginine to the skin twice daily for 3 months is less effective than surgery for treating anal fissures. However, applying a topical gel containing L-arginine five times daily for at least 12 weeks might heal anal fissues in people who do not respond to traditional care.
  • Breast cancer. Early research shows that taking L-arginine before chemotherapy does not improve the response rate in people with breast cancer.
  • Chemotherapy side effects. Early research shows that taking L-argnine before starting chemotherapy can prevent the reduction in immune system activity that is associated with chemotherapy treatment in people with breast cancer.
  • Congestive heart failure. Taking L-arginine by mouth, together with conventional treatment, seems to improve kidney function in people with heart failure. However, it might not improve the ability to exercise, quality of life, or blood circulation. L-arginine should not be used in place of conventional treatment.
  • Clogged blood vessels (coronary artery disease). Early research suggests that taking L-arginine intravenously (by IV) before exercising can improve blood vessel function in people with coronary artery disease. Howeve, it does not improve blood flow to the heart.
  • Critical illness (trauma). Research shows that taking L-arginine by mouth with glutamine, nucleotides, and omega-3 fatty acids reduces the recovery time, need for ventilation, and risk of infections in people who are critically ill. However, it does not reduce the risk of death.
  • Memory loss (dementia). Early research suggests that L-argnine might improve memory loss related to aging.
  • Cavities. Early research suggests that using a sugarless mint containing an arginine complex (CaviStat) for one year reduces the number of cavaties in molars of children compared with sugarless mints that do not contain arginine.
  • Sensitive teeth. Early research suggests that using a tootherpaste containing arginine, calcium, and fluoride reduces tooth sensitivity when used twice daily.
  • Diabetes. Taking L-arginine by mouth for one month seems to improve blood sugar control in people with diabetes. L-arginine also seems to improve insulin sensitivity and blood pressure in people with type 2 diabetes.
  • Diabetic foot ulcers. Early research shows that applying L-arginine to the feet daily can improve circulation in people with diabetes, which might be helpful in preventing diabetic foot ulcers.However, if there is already an ulcer on the foot, injecting L-arginine under the skin near the ulcer does not seem to shorten healing time or lower the chance of needing an amputation in the future.
  • Nerve damage due to diabetes. Early research suggests that taking L-arginine daily for 3 months does not improve nerve damage related to diabetes.
  • Muscle problems in the esophagus. Early research suggests that receiving an L-arginine infusion and taking L-arginine by mouth for 6 weeks reduces the number and intensity of chest pain attackes in people with muscle problems in the esophagus and chest pain that is not related to the heart.
  • Exercise performance. There is inconsistent evidence about the effects of L-arginine on exercise performance. Some evidence shows that taking 6 grams of L-arginine in a drink increases exercise time. However, other evidence suggests that taking L-arginine, alone or together with antioxidants (Niteworks, Herbalife International, Inc), does not improve performance in male cyclists.
  • Head and neck cancer. Supplementing a feeding tube with L-argnine does not seem to improve immune function, reduce tumor size, or improve healing in people with head and neck cancer.
  • Coronary artery bypass graft (CABG) surgery. There is mixed evidence about the effects of L-arginine in protecting the heart during CABG. Early research suggests that administering L-arginine intravenously (by IV) helps maintain pressure in the arteries and blood flow in people undergoing CABG. However, it does not reduce complications after surgery or the amount of time spent in the hospital.
  • Heart transplant. Early research suggests that taking L-argnine by mouth for 6 weeks increases walking distance and improves breathing in people with a heart transplant.
  • Infertility. There is inconsistent evidence about the effectiveness of L-arginine for infertility. Some early research suggests that taking 16 grams of L-arginine daily increases egg counts collected in women undergoing IVF. However, it does not seem to improve pregnancy rates. Other research suggests that taking L-arginine does not improve semen quality in men with unexplained infertility.
  • Bladder inflammation. Taking L-arginine by mouth seems to reduce pain and some symptoms of bladder inflammation, although improvements may take 3 months to occur. However, L-arginine does not seem to reduce the need to urinate at night or improve the frequency of urination.
  • Poor growth of fetus during pregnancy. Early research suggests that taking L-arginine during pregnancy can incrase the birthweight of babies who show poor growth while still in their mother’s womb. However, L-arginine does not seem to increase birthweight or reduce the risk of the baby dying if the baby has extremely poor growth while in the wom.
  • Genetic condition affecting many body systems (MELAS syndrome). There is some interest in using L-arginine to improve sympstoms asoicated with MELAS syndrome. Early research suggests that administering L-arginine intravenously (by IV) within one hour of stroke-like symptoms improves headaches, nausea, vomiting, blindness, and the appearance of bright spots.
  • Migraine headache. Taking L-arginine by mouth along with the painkiller ibuprofen seems to be effective for treating migraine headache. This combination sometimes starts to work within 30 minutes. However, it is hard to know how much of the pain relief is due to L-arginine, since ibuprofen can relieve migraine pain on its own.
  • Ovarian disease (polycystic ovarian syndrome). Early research suggests that taking N-acetyl-cysteine and L-arginine daily for 6 months can improve menstrual function and reduces insulin resistance in people with polycystic ovarian syndrome.
  • Pressure ulcers. Taking L-arginine by mouth along with the painkiller ibuprofen seems to be effective for treating migraine headache. This combination sometimes starts to work within 30 minutes. However, it is hard to know how much of the pain relief is due to L-arginine, since ibuprofen can relieve migraine pain on its own.
  • Restricted blood flow (restenosis). Some evidence suggests that administering L-arginine during stent implantation followed by L-arginine supplementation by mouth for 2 weeks after stent implantation does not reduce the risk of restricted blood flow. However, other evidence suggests that administering L-arginine at the site of stent implantation may reduce artery wall thickening.
  • Kidney transplant. There is inconsistent evidence about the effects of L-arginine for people with kidney transplants. Early research suggests that taking L-arginine intravenously (by IV) improves kidney function. However, other evidence suggests that L-arginine does not improve kidney function. The inconsistencies may be due to other factors related to the transplant procedure.
  • Respiratory infections. Early research suggests that taking L-arginine by mouth for 60 days prevents the recurrence of respiratory infections in children.
  • Sickle-cell disease. Early research suggests that taking L-arginine for 5 days might be useful for people with sickle cell disease who have high blood pressure in the lungs.
  • Stress. Some early research suggests that taking a combination of L-lysine and L-arginine for up to 10 days reduces stress and anxiety in healthy people and those prone to stress.
  • Prevention of the common cold.
  • Female sexual problems.
More evidence is needed to rate the effectiveness of L-arginine for these uses.

How does it work?

Return to top
L-arginine is converted in the body into a chemical called nitric oxide. Nitric oxide causes blood vessels to open wider for improved blood flow. L-arginine also stimulates the release of growth hormone, insulin, and other substances in the body.

Are there safety concerns?

Return to top
L-arginine is POSSIBLY SAFE for most people when taken appropriately by mouth, administered as a shot, or applied to the skin, short-term. It can cause some side effects such as abdominal pain, bloating, diarrhea, gout, blood abnormalities, allergies, airway inflammation, worsening of asthma, and low blood pressure.

Special precautions & warnings:

Pregnancy and breast-feeding: L-arginine is POSSIBLY SAFE when taken by mouth appropriately for a short-term during pregnancy. Not enough is known about using L-arginine long-term in pregnancy or during breast-feeding. Stay on the safe side and avoid use.

Children: L-arginine is POSSIBLY SAFE when used by mouth in premature infants in appropriate doses. However, L-arginine is POSSIBLY UNSAFE when used in high doses. Doses that are too high can cause serious side effects including death in children.

Allergies or asthma: L-arginine can cause an allergic response or make swelling in the airways worse. If you are prone to allergies or asthma and decide to take L-arginine, use it with caution.

Cirrhosis: L-arginine should be used with caution in people with cirrhosis.

Guanidinoacetate methyltransferase deficiency: People with this inherited condition are unable to convert arginine and other similar chemicals into creatine. To prevent complications associated with this condition, these people should should not take arginine.

Herpes: There is a concern that L-arginine might make herpes worse. There is some evidence that L-arginine is needed for the herpes virus to multiply.

Low blood pressure: L-arginine might lower blood pressure. This could be a problem if you already have low blood pressure.

Recent heart attack: There is a concern that L-arginine might increase the risk of death after a heart attack, especially in older people. If you have had a heart attack recently, don’t take L-arginine.

Kidney disease: Arginine can cause fatal complications in people with kidney disease.

Surgery: L-arginine might affect blood pressure. There is a concern that it might interfere with blood pressure control during and after surgery. Stop taking L-arginine at least 2 weeks before a scheduled surgery.

Are there interactions with medications?

Return to top


Do not take this combination.

Medications for high blood pressure (Antihypertensive drugs)
L-arginine seems to decrease blood pressure. Taking L-arginine along with medications for high blood pressure might cause your blood pressure to go too low.

Some medications for high blood pressure include captopril (Capoten), enalapril (Vasotec), losartan (Cozaar), valsartan (Diovan), diltiazem (Cardizem), amlodipine (Norvasc), hydrochlorothiazide (HydroDIURIL), furosemide (Lasix), and many others.


Be cautious with this combination.

Medications for diabetes (Antidiabetes drugs)
L-arginine seems to decrease blood sugar in people with type 2 diabetes. Diabetes medications are also used to lower blood sugar. Taking L-arginine along with diabetes medications might cause your blood sugar to go too low. Monitor your blood sugar closely. The dose of your diabetes medication might need to be changed.

Some medications used for diabetes include glimepiride (Amaryl), glyburide (DiaBeta, Glynase PresTab, Micronase), insulin, pioglitazone (Actos), rosiglitazone (Avandia), chlorpropamide (Diabinese), glipizide (Glucotrol), tolbutamide (Orinase), and others.

Medications for high blood pressure (ACE inhibitors)
L-arginine seems to decrease blood pressure. Taking L-arginine along with certain medications for high blood pressure, called ACE inhibitors might cause your blood pressure to go too low. Also, ACE inhibitors can increase potassium levels. L-arginine may also increase potassium levels. Taking L-arginine with ACE inhibitors might cause potassium levels to become to high.

Some ACE inhibitors include benazepril (Lotensin), captopril (Capoten), enalapril (Vasotec), fosinopril (Monopril), lisinopril (Prinivil, Zestril), moexipril (Univasc), perindopril (Aceon), quinapril (Accupril), ramipril (Altace), and trandolapril (Mavik).

Medications for high blood pressure (Angiotensin receptor blockers (ARBs))
L-arginine seems to decrease blood pressure. Taking L-arginine along with medications for high blood pressure might cause your blood pressure to go too low.

The ARBs include losartan (Cozaar), valsartan (Diovan), irbesartan (Avapro), candesartan (Atacand), telmisartan (Micardis), and eprosartan (Teveten).

Medications for high blood pressure (Isoproterenol)
L-arginine seems to decrease blood pressure. Isoproterenol is a drug that is used to lower blood pressure. Taking L-arginine along with isoproterenol might cause your blood pressure to go too low.

Medications that increase blood flow to the heart (Nitrates)
L-arginine increases blood flow. Taking L-arginine with medications that increase blood flow to the heart might increase the chance of dizziness and lightheadedness.

Some of these medications that increase blood flow to the heart include nitroglycerin (Nitro-Bid, Nitro-Dur, Nitrostat), and isosorbide (Imdur, Isordil, Sorbitrate).

Medications that slow blood clotting (Anticoagulant / Antiplatelet drugs)
L-arginine seems to slow blood clotting. Taking L-arginine along with medications that also slow clotting might increase the chances of bruising and bleeding.

Some medications that slow blood clotting include aspirin, clopidogrel (Plavix), dalteparin (Fragmin), enoxaparin (Lovenox), heparin, ticlopidine (Ticlid), warfarin (Coumadin), and others.

Sildenafil (Viagra)
Sildenafil (Viagra) can lower blood pressure. L-arginine can also lower blood pressure. Taking sildenafil (Viagra) and L-arginine together might cause the blood pressure to go too low. Blood pressure that is too low can cause dizziness and other side effects.

Water pills (Potassium-sparing diuretics)
L-arginine might increase potassium levels in the body. Some "water pills" might also increase potassium in the body. In theory, taking L-arginine along with some "water pills" might cause too much potassium to be in the body. Some water pills include amiloride (Midamor), spironolactone (Aldactone), and triamterene (Dyrenium).

Some "water pills" that increase potassium in the body include spironolactone (Aldactone), triamterene (Dyrenium), and amiloride (Midamor).

Are there interactions with herbs and supplements?

Return to top
Herbs and supplements that might lower blood pressure
L-arginine seems to lower blood pressure. Using it along with other herbs and supplements that have this same effect might increase the risk of blood pressure dropping too low in some people. Some of these products include andrographis, casein peptides, cat's claw, coenzyme Q-10, fish oil, L-arginine, lycium, stinging nettle, theanine, and others.

Herbs and supplements that might lower blood sugar
L-arginine seems to lower blood sugar. Using it along with other herbs and supplements that have the same effect might cause blood sugar to become too low in some people. Some of these products include devil's claw, fenugreek, guar gum, Panax ginseng, Siberian ginseng, and others.

Herbs and supplements that might slow blood clotting
Using L-arginine along with herbs that can slow blood clotting could increase the risk of bleeding in some people. These herbs include angelica, clove, danshen, garlic, ginkgo, Panax ginseng, red clover, turmeric, and others.

L-arginine can cause an organ in the body called the pancreas to release a hormone called glucagon. Glucagon comes to the rescue when blood sugar levels are too low. Glucagon makes the liver convert stored sugar to useable sugar that is released into the bloodstream. Using L-arginine along with xylitol can keep L-arginine from stimulating the pancreas to release glucagon.

Are there interactions with foods?

Return to top
There are no known interactions with foods.

What dose is used?

Return to top
The following doses have been studied in scientific research:

  • For congestive heart failure: doses range from 6-20 grams per day, as three divided doses.
  • For chest pain associated with coronary artery disease (angina pectoris): 3-6 grams three times per day for up to one month.
  • For preventing the loss of the effectiveness of nitroglycerin in relieving pain in people with chest pain due to coronary artery disease (angina pectoris): 700 mg four times daily.
  • For organic erectile dysfunction (ED): 5 grams per day. Taking lower doses might not be effective.
  • For preventing inflammation of the digestive tract in premature infants: 261 mg/kg added to oral feedings daily for the first 28 days of life.

Other names

Return to top
2-Amino-5-guanidinopentanoic Acid, (2S)-2-Amino-5-{[amino (imino) methyl]amino}pentanoic Acid, Acide 2-Amino-5-guanidinopentanoïque, Arg, Arginine, Arginine Ethyl Ester, Arginine Ethyl Ester Dihydrochloride, Arginine Ethyl Ester HCl, Arginine HCl, Arginine Hydrochloride, Di-Arginine Malate, Di-Arginine Orotate, Di-L-Arginine-L-Malate, Dl-Arginine, L-Arginina, L-Arginine Ethyl Ester Dichloride, L-Arginine HCl, L-Arginine Hexanoate, L-Arginine Hydrochloride, L-Arginine Ketoisocaproic Acid, L-Arginine L-Pyroglutamate, L-Arginine Pyroglutamate, L-Arginine Taurinate, Malate de Di-Arginine, Orotate de Di-Arginine, R-Gene 10.


Return to top
To learn more about how this article was written, please see the Natural Medicines Comprehensive Database methodology.methodology (


Return to top
To see all references for the L-arginine page, please go to

  1. O'Rourke, D. J., Ryan, S., Salomons, G., Jakobs, C., Monavari, A., and King, M. D. Guanidinoacetate methyltransferase (GAMT) deficiency: late onset of movement disorder and preserved expressive language. Dev.Med.Child Neurol. 2009;51:404-407. View abstract.
  2. Claris-Appiani, A., Ardissino, G., Coppo, R., Bonaudo, R., Dacco, V., Bettinelli, A., and Tirelli, A. S. Effect of renal function of arginine supplementation in children with chronic renal insufficiency. Journal of the American Society of Nephrology 1993;4:766.
  3. Eshghi F. The efficacy of L-arginine gel for treatment of chronic anal fissure compared to surgical sphincterotomy. Journal of Medical Sciences. 2007;7:481-484.
  4. Quyyumi, A. A. Does acute improvement of endothelial dysfunction in coronary artery disease improve myocardial ischemia? A double-blind comparison of parenteral D- and L-arginine. J Am Coll.Cardiol 1998;32:904-911. View abstract.
  5. Baligan, M., Giardina, A., Giovannini, G., Laghi, M. G., and Ambrosioni, G. [L-arginine and immunity. Study of pediatric subjects]. Minerva Pediatr 1997;49:537-542. View abstract.
  6. Bortolotti, M., Brunelli, F., Sarti, P., and Miglioli, M. Clinical and manometric effects of L-arginine in patients with chest pain and oesophageal motor disorders. Ital J Gastroenterol.Hepatol. 1997;29:320-324. View abstract.
  7. Heys, S. D., Ogston, K., Miller, I., Hutcheon, A. W., Walker, L. G., Sarker, T. K., Dewar, J., Ah-See, A. K., and Eremin, O. Potentiation of the response to chemotherapy in patients with breast cancer by dietary supplementation with L-arginine: results of a randomised controlled trial. Int.J Oncol. 1998;12:221-225. View abstract.
  8. Marietta, M., Facchinetti, F., Neri, I., Piccinini, F., Volpe, A., and Torelli, G. L-arginine infusion decreases platelet aggregation through an intraplatelet nitric oxide release. Thromb.Res 10-15-1997;88:229-235. View abstract.
  9. Smith, S. D., Wheeler, M. A., Foster, H. E., Jr., and Weiss, R. M. Improvement in interstitial cystitis symptom scores during treatment with oral L-arginine. J Urol. 1997;158(3 Pt 1):703-708. View abstract.
  10. Wolf, A., Zalpour, C., Theilmeier, G., Wang, B. Y., Ma, A., Anderson, B., Tsao, P. S., and Cooke, J. P. Dietary L-arginine supplementation normalizes platelet aggregation in hypercholesterolemic humans. J Am Coll.Cardiol 3-1-1997;29:479-485. View abstract.
  1. Giugliano, D., Marfella, R., Verrazzo, G., Acampora, R., Coppola, L., Cozzolino, D., and D'Onofrio, F. The vascular effects of L-Arginine in humans. The role of endogenous insulin. J Clin.Invest 2-1-1997;99:433-438. View abstract.
  2. Marfella, R., Acampora, R., Verrazzo, G., Ziccardi, P., De, Rosa N., Giunta, R., and Giugliano, D. Metformin improves hemodynamic and rheological responses to L-arginine in NIDDM patients. Diabetes Care 1996;19:934-939. View abstract.
  3. Kirk, S. J., Hurson, M., Regan, M. C., Holt, D. R., Wasserkrug, H. L., and Barbul, A. Arginine stimulates wound healing and immune function in elderly human beings. Surgery 1993;114:155-159. View abstract.
  4. Brittenden, J., Heys, S. D., Ross, J., Park, K. G., and Eremin, O. Natural cytotoxicity in breast cancer patients receiving neoadjuvant chemotherapy: effects of L-arginine supplementation. Eur.J Surg.Oncol. 1994;20:467-472. View abstract.
  5. Bode-Boger, S. M., Boger, R. H., Creutzig, A., Tsikas, D., Gutzki, F. M., Alexander, K., and Frolich, J. C. L-arginine infusion decreases peripheral arterial resistance and inhibits platelet aggregation in healthy subjects. Clin.Sci.(Lond) 1994;87:303-310. View abstract.
  6. Wolf, S. C., Erley, C. M., Kenner, S., Berger, E. D., and Risler, T. Does L-arginine alter proteinuria and renal hemodynamics in patients with chronic glomerulonephritis and hypertension? Clin.Nephrol. 1995;43 Suppl 1:S42-S46. View abstract.
  7. Higashi, Y., Oshima, T., Ozono, R., Watanabe, M., Matsuura, H., and Kajiyama, G. Effects of L-arginine infusion on renal hemodynamics in patients with mild essential hypertension. Hypertension 1995;25(4 Pt 2):898-902. View abstract.
  8. Gaston, R. S., Schlessinger, S. D., Sanders, P. W., Barker, C. V., Curtis, J. J., and Warnock, D. G. Cyclosporine inhibits the renal response to L-arginine in human kidney transplant recipients. J Am Soc Nephrol. 1995;5:1426-1433. View abstract.
  9. Dell'Omo, G., Catapano, G., Ebel, M., Gazzano, A., Ducci, M., Del, Chicca M., Clerico, A., and Pedrinelli, R. [Pressor, renal and endocrine effects of systemic infusion of L-arginine in hypertensive patients]. Ann.Ital Med.Int. 1995;10:107-112. View abstract.
  10. Adams, M. R., Forsyth, C. J., Jessup, W., Robinson, J., and Celermajer, D. S. Oral L-arginine inhibits platelet aggregation but does not enhance endothelium-dependent dilation in healthy young men. J Am Coll.Cardiol 1995;26:1054-1061. View abstract.
  11. Bushinsky, D. A. and Gennari, F. J. Life-threatening hyperkalemia induced by arginine. Ann.Intern.Med. 1978;89(5 Pt 1):632-634. View abstract.
  12. Hertz, P. and Richardson, J. A. Arginine-induced hyperkalemia in renal failure patients. Arch.Intern.Med. 1972;130:778-780. View abstract.
  13. Pryor, J. P., Blandy, J. P., Evans, P., Chaput De Saintonge, D. M., and Usherwood, M. Controlled clinical trial of arginine for infertile men with oligozoospermia. Br J Urol. 1978;50:47-50. View abstract.
  14. Marti-Carvajal, A. J., Knight-Madden, J. M., and Martinez-Zapata, M. J. Interventions for treating leg ulcers in people with sickle cell disease. Cochrane.Database.Syst.Rev. 2012;11:CD008394. View abstract.
  15. Dong, J. Y., Qin, L. Q., Zhang, Z., Zhao, Y., Wang, J., Arigoni, F., and Zhang, W. Effect of oral L-arginine supplementation on blood pressure: a meta-analysis of randomized, double-blind, placebo-controlled trials. Am.Heart J 2011;162:959-965. View abstract.
  16. Drover, J. W., Dhaliwal, R., Weitzel, L., Wischmeyer, P. E., Ochoa, J. B., and Heyland, D. K. Perioperative use of arginine-supplemented diets: a systematic review of the evidence. J Am.Coll.Surg. 2011;212:385-99, 399. View abstract.
  17. Neri, I., Monari, F., Sgarbi, L., Berardi, A., Masellis, G., and Facchinetti, F. L-arginine supplementation in women with chronic hypertension: impact on blood pressure and maternal and neonatal complications. J Matern.Fetal Neonatal Med. 2010;23:1456-1460. View abstract.
  18. Saleh, A. I., Abdel Maksoud, S. M., El-Maraghy, S. A., and Gad, M. Z. Protective effect of L-arginine in experimentally induced myocardial ischemia: comparison with aspirin. J Cardiovasc.Pharmacol.Ther 2011;16:53-62. View abstract.
  19. Lakhan, S. E. and Vieira, K. F. Nutritional and herbal supplements for anxiety and anxiety-related disorders: systematic review. Nutr J 2010;9:42. View abstract.
  20. Bailey, S. J., Winyard, P. G., Vanhatalo, A., Blackwell, J. R., DiMenna, F. J., Wilkerson, D. P., and Jones, A. M. Acute L-arginine supplementation reduces the O2 cost of moderate-intensity exercise and enhances high-intensity exercise tolerance. J Appl.Physiol 2010;109:1394-1403. View abstract.
  21. Hughes, N., Mason, S., Jeffery, P., Welton, H., Tobin, M., O'Shea, C., and Browne, M. A comparative clinical study investigating the efficacy of a test dentifrice containing 8% strontium acetate and 1040 ppm sodium fluoride versus a marketed control dentifrice containing 8% arginine, calcium carbonate, and 1450 ppm sodium monofluorophosphate in reducing dentinal hypersensitivity. J Clin.Dent. 2010;21:49-55. View abstract.
  22. Marik, P. E. and Zaloga, G. P. Immunonutrition in high-risk surgical patients: a systematic review and analysis of the literature. JPEN J Parenter.Enteral Nutr 2010;34:378-386. View abstract.
  23. Sunderland, K. L., Greer, F., and Morales, J. VO2max and ventilatory threshold of trained cyclists are not affected by 28-day L-arginine supplementation. J Strength.Cond.Res 2011;25:833-837. View abstract.
  24. Ast, J., Jablecka, A., Bogdanski, P., Smolarek, I., Krauss, H., and Chmara, E. Evaluation of the antihypertensive effect of L-arginine supplementation in patients with mild hypertension assessed with ambulatory blood pressure monitoring. Med.Sci.Monit. 2010;16:CR266-CR271. View abstract.
  25. Camic, C. L., Housh, T. J., Zuniga, J. M., Hendrix, R. C., Mielke, M., Johnson, G. O., and Schmidt, R. J. Effects of arginine-based supplements on the physical working capacity at the fatigue threshold. J Strength.Cond.Res 2010;24:1306-1312. View abstract.
  26. Chen, S., Kim, W., Henning, S. M., Carpenter, C. L., and Li, Z. Arginine and antioxidant supplement on performance in elderly male cyclists: a randomized controlled trial. J Int.Soc Sports Nutr. 2010;7:13. View abstract.
  27. Jude, E. B., Dang, C., and Boulton, A. J. Effect of L-arginine on the microcirculation in the neuropathic diabetic foot in Type 2 diabetes mellitus: a double-blind, placebo-controlled study. Diabet.Med. 2010;27:113-116. View abstract.
  28. Fontanive, P., Saponati, G., Iurato, A., Volterrani, C., Boni, A., Piccioni, L., and Dini, F. L. Effects of L-arginine on the Minnesota Living with Heart Failure Questionnaire quality-of-life score in patients with chronic systolic heart failure. Med.Sci.Monit. 2009;15:CR606-CR611. View abstract.
  29. Sun, T., Zhou, W. B., Luo, X. P., Tang, Y. L., and Shi, H. M. Oral L-arginine supplementation in acute myocardial infarction therapy: a meta-analysis of randomized controlled trials. Clin.Cardiol 2009;32:649-652. View abstract.
  30. Ozbek, M., Erdogan, M., Karadeniz, M., Cetinkalp, S., Ozgen, A. G., Saygili, F., Yilmaz, C., and Tuzun, M. Evaluation of beta cell dysfunction by mixed meal tolerance test and oral L-arginine in patients with newly diagnosed type 2 diabetes mellitus. Exp.Clin.Endocrinol.Diabetes 2009;117:573-576. View abstract.
  31. Docimo, R., Montesani, L., Maturo, P., Costacurta, M., Bartolino, M., Zhang, Y. P., DeVizio, W., Delgado, E., Cummins, D., Dibart, S., and Mateo, L. R. Comparing the efficacy in reducing dentin hypersensitivity of a new toothpaste containing 8.0% arginine, calcium carbonate, and 1450 ppm fluoride to a benchmark commercial desensitizing toothpaste containing 2% potassium ion: an eight-week clinical study in Rome, Italy. J Clin.Dent. 2009;20:137-143. View abstract.
  32. Nathoo, S., Delgado, E., Zhang, Y. P., DeVizio, W., Cummins, D., and Mateo, L. R. Comparing the efficacy in providing instant relief of dentin hypersensitivity of a new toothpaste containing 8.0% arginine, calcium carbonate, and 1450 ppm fluoride relative to a benchmark desensitizing toothpaste containing 2% potassium ion and 1450 ppm fluoride, and to a control toothpaste with 1450 ppm fluoride: a three-day clinical study in New Jersey, USA. J Clin.Dent. 2009;20:123-130. View abstract.
  33. Ayad, F., Ayad, N., Delgado, E., Zhang, Y. P., DeVizio, W., Cummins, D., and Mateo, L. R. Comparing the efficacy in providing instant relief of dentin hypersensitivity of a new toothpaste containing 8.0% arginine, calcium carbonate, and 1450 ppm fluoride to a benchmark desensitizing toothpaste containing 2% potassium ion and 1450 ppm fluoride, and to a control toothpaste with 1450 ppm fluoride: a three-day clinical study in Mississauga, Canada. J Clin.Dent. 2009;20:115-122. View abstract.
  34. Koppo, K., Taes, Y. E., Pottier, A., Boone, J., Bouckaert, J., and Derave, W. Dietary arginine supplementation speeds pulmonary VO2 kinetics during cycle exercise. Med.Sci.Sports Exerc. 2009;41:1626-1632. View abstract.
  35. Masha, A., Manieri, C., Dinatale, S., Bruno, G. A., Ghigo, E., and Martina, V. Prolonged treatment with N-acetylcysteine and L-arginine restores gonadal function in patients with polycystic ovary syndrome. J Endocrinol.Invest 2009;32:870-872. View abstract.
  36. Jovanovic, A., Gerrard, J., and Taylor, R. The second-meal phenomenon in type 2 diabetes. Diabetes Care 2009;32:1199-1201. View abstract.
  37. Winer, N., Branger, B., Azria, E., Tsatsaris, V., Philippe, H. J., Roze, J. C., Descamps, P., Boog, G., Cynober, L., and Darmaun, D. L-Arginine treatment for severe vascular fetal intrauterine growth restriction: a randomized double-bind controlled trial. Clin.Nutr. 2009;28:243-248. View abstract.
  38. Stanislavov, R., Nikolova, V., and Rohdewald, P. Improvement of seminal parameters with Prelox: a randomized, double-blind, placebo-controlled, cross-over trial. Phytother.Res 2009;23:297-302. View abstract.
  39. Heyman, H., Van De Looverbosch, D. E., Meijer, E. P., and Schols, J. M. Benefits of an oral nutritional supplement on pressure ulcer healing in long-term care residents. J Wound Care 2008;17:476-8, 480. View abstract.
  40. Acevedo, A. M., Montero, M., Rojas-Sanchez, F., Machado, C., Rivera, L. E., Wolff, M., and Kleinberg, I. Clinical evaluation of the ability of CaviStat in a mint confection to inhibit the development of dental caries in children. J Clin.Dent. 2008;19:1-8. View abstract.
  41. Casas-Rodera, P., Gomez-Candela, C., Benitez, S., Mateo, R., Armero, M., Castillo, R., and Culebras, J. M. Immunoenhanced enteral nutrition formulas in head and neck cancer surgery: a prospective, randomized clinical trial. Nutr.Hosp. 2008;23:105-110. View abstract.
  42. Ruel, M., Beanlands, R. S., Lortie, M., Chan, V., Camack, N., deKemp, R. A., Suuronen, E. J., Rubens, F. D., DaSilva, J. N., Sellke, F. W., Stewart, D. J., and Mesana, T. G. Concomitant treatment with oral L-arginine improves the efficacy of surgical angiogenesis in patients with severe diffuse coronary artery disease: the Endothelial Modulation in Angiogenic Therapy randomized controlled trial. J Thorac.Cardiovasc.Surg. 2008;135:762-70, 770. View abstract.
  43. Tarumoto, T., Imagawa, S., Kobayashi, M., Hirayama, A., Ozawa, K., and Nagasawa, T. L-arginine administration reverses anemia associated with renal disease. Int.J Hematol. 2007;86:126-129. View abstract.
  44. Wilson, A. M., Harada, R., Nair, N., Balasubramanian, N., and Cooke, J. P. L-arginine supplementation in peripheral arterial disease: no benefit and possible harm. Circulation 7-10-2007;116:188-195. View abstract.
  45. Facchinetti, F., Saade, G. R., Neri, I., Pizzi, C., Longo, M., and Volpe, A. L-arginine supplementation in patients with gestational hypertension: a pilot study. Hypertens.Pregnancy. 2007;26:121-130. View abstract.
  46. Lucotti, P., Setola, E., Monti, L. D., Galluccio, E., Costa, S., Sandoli, E. P., Fermo, I., Rabaiotti, G., Gatti, R., and Piatti, P. Beneficial effects of a long-term oral L-arginine treatment added to a hypocaloric diet and exercise training program in obese, insulin-resistant type 2 diabetic patients. Am J Physiol Endocrinol.Metab 2006;291:E906-E912. View abstract.
  47. Neri, I., Jasonni, V. M., Gori, G. F., Blasi, I., and Facchinetti, F. Effect of L-arginine on blood pressure in pregnancy-induced hypertension: a randomized placebo-controlled trial. J Matern.Fetal Neonatal Med. 2006;19:277-281. View abstract.
  48. Hladunewich, M. A., Derby, G. C., Lafayette, R. A., Blouch, K. L., Druzin, M. L., and Myers, B. D. Effect of L-arginine therapy on the glomerular injury of preeclampsia: a randomized controlled trial. Obstet.Gynecol. 2006;107:886-895. View abstract.
  49. Colagrande, L., Formica, F., Porta, F., Martino, A., Sangalli, F., Avalli, L., and Paolini, G. Reduced cytokines release and myocardial damage in coronary artery bypass patients due to L-arginine cardioplegia supplementation. Ann.Thorac.Surg. 2006;81:1256-1261. View abstract.
  50. Oka, R. K., Szuba, A., Giacomini, J. C., and Cooke, J. P. A pilot study of L-arginine supplementation on functional capacity in peripheral arterial disease. Vasc.Med. 2005;10:265-274. View abstract.
  51. Mansoor, J. K., Morrissey, B. M., Walby, W. F., Yoneda, K. Y., Juarez, M., Kajekar, R., Severinghaus, J. W., Eldridge, M. W., and Schelegle, E. S. L-arginine supplementation enhances exhaled NO, breath condensate VEGF, and headache at 4,342 m. High Alt.Med.Biol. 2005;6:289-300. View abstract.
  52. Gosselink, M. P., Darby, M., Zimmerman, D. D., Gruss, H. J., and Schouten, W. R. Treatment of chronic anal fissure by application of L-arginine gel: a phase II study in 15 patients. Dis Colon Rectum 2005;48:832-837. View abstract.
  53. Koga, Y., Akita, Y., Nishioka, J., Yatsuga, S., Povalko, N., Tanabe, Y., Fujimoto, S., and Matsuishi, T. L-arginine improves the symptoms of strokelike episodes in MELAS. Neurology 2-22-2005;64:710-712. View abstract.
  54. Rytlewski, K., Olszanecki, R., Korbut, R., and Zdebski, Z. Effects of prolonged oral supplementation with l-arginine on blood pressure and nitric oxide synthesis in preeclampsia. Eur.J Clin.Invest 2005;35:32-37. View abstract.
  55. Xiao, X. M. and Li, L. P. L-Arginine treatment for asymmetric fetal growth restriction. Int.J Gynaecol.Obstet. 2005;88:15-18. View abstract.
  56. Neri, I., Blasi, I., and Facchinetti, F. Effects of acute L-arginine infusion on non-stress test in hypertensive pregnant women. J Matern.Fetal Neonatal Med. 2004;16:23-26. View abstract.
  57. Schlaich, M. P., Ahlers, B. A., Parnell, M. M., and Kaye, D. M. beta-Adrenoceptor-mediated, nitric-oxide-dependent vasodilatation is abnormal in early hypertension: restoration by L-arginine. J Hypertens. 2004;22:1917-1925. View abstract.
  58. Sieroszewski, P., Suzin, J., and Karowicz-Bilinska, A. Ultrasound evaluation of intrauterine growth restriction therapy by a nitric oxide donor (L-arginine). J Matern.Fetal Neonatal Med. 2004;15:363-366. View abstract.
  59. Dudek, D., Legutko, J., Heba, G., Bartus, S., Partyka, L., Huk, I., Dembinska-Kiec, A., Kaluza, G. L., and Dubiel, J. S. L-arginine supplementation does not inhibit neointimal formation after coronary stenting in human beings: an intravascular ultrasound study. Am Heart J 2004;147:E12. View abstract.
  60. Palloshi, A., Fragasso, G., Piatti, P., Monti, L. D., Setola, E., Valsecchi, G., Galluccio, E., Chierchia, S. L., and Margonato, A. Effect of oral L-arginine on blood pressure and symptoms and endothelial function in patients with systemic hypertension, positive exercise tests, and normal coronary arteries. Am J Cardiol 4-1-2004;93:933-935. View abstract.
  61. Stokes, G. S., Barin, E. S., Gilfillan, K. L., and Kaesemeyer, W. H. Interactions of L-arginine, isosorbide mononitrate, and angiotensin II inhibitors on arterial pulse wave. Am J Hypertens. 2003;16(9 Pt 1):719-724. View abstract.
  62. Sydow, K., Schwedhelm, E., Arakawa, N., Bode-Boger, S. M., Tsikas, D., Hornig, B., Frolich, J. C., and Boger, R. H. ADMA and oxidative stress are responsible for endothelial dysfunction in hyperhomocyst(e)inemia: effects of L-arginine and B vitamins. Cardiovasc.Res 2003;57:244-252. View abstract.
  63. Miller, H. I., Dascalu, A., Rassin, T. A., Wollman, Y., Chernichowsky, T., and Iaina, A. Effects of an acute dose of L-arginine during coronary angiography in patients with chronic renal failure: a randomized, parallel, double-blind clinical trial. Am J Nephrol. 2003;23:91-95. View abstract.
  64. Cassone, Faldetta M., Laurenti, O., Desideri, G., Bravi, M. C., De, Luca O., Marinucci, M. C., De, Mattia G., and Ferri, C. L-arginine infusion decreases plasma total homocysteine concentrations through increased nitric oxide production and decreased oxidative status in Type II diabetic patients. Diabetologia 2002;45:1120-1127. View abstract.
  65. Schramm, L., La, M., Heidbreder, E., Hecker, M., Beckman, J. S., Lopau, K., Zimmermann, J., Rendl, J., Reiners, C., Winderl, S., Wanner, C., and Schmidt, H. H. L-arginine deficiency and supplementation in experimental acute renal failure and in human kidney transplantation. Kidney Int. 2002;61:1423-1432. View abstract.
  66. Carrier, M., Pellerin, M., Perrault, L. P., Bouchard, D., Page, P., Searle, N., and Lavoie, J. Cardioplegic arrest with L-arginine improves myocardial protection: results of a prospective randomized clinical trial. Ann.Thorac.Surg. 2002;73:837-841. View abstract.
  67. Suzuki, T., Hayase, M., Hibi, K., Hosokawa, H., Yokoya, K., Fitzgerald, P. J., Yock, P. G., Cooke, J. P., Suzuki, T., and Yeung, A. C. Effect of local delivery of L-arginine on in-stent restenosis in humans. Am J Cardiol 2-15-2002;89:363-367. View abstract.
  68. Zhang, X. Z., Ardissino, G., Ghio, L., Tirelli, A. S., Dacco, V., Colombo, D., Pace, E., Testa, S., and Claris-Appiani, A. L-arginine supplementation in young renal allograft recipients with chronic transplant dysfunction. Clin.Nephrol. 2001;55:453-459. View abstract.
  69. Piatti, P. M., Monti, L. D., Valsecchi, G., Magni, F., Setola, E., Marchesi, F., Galli-Kienle, M., Pozza, G., and Alberti, K. G. Long-term oral L-arginine administration improves peripheral and hepatic insulin sensitivity in type 2 diabetic patients. Diabetes Care 2001;24:875-880. View abstract.
  70. Nagaya, N., Uematsu, M., Oya, H., Sato, N., Sakamaki, F., Kyotani, S., Ueno, K., Nakanishi, N., Yamagishi, M., and Miyatake, K. Short-term oral administration of L-arginine improves hemodynamics and exercise capacity in patients with precapillary pulmonary hypertension. Am J Respir.Crit Care Med. 2001;163:887-891. View abstract.
  71. Bednarz, B., Wolk, R., Chamiec, T., Herbaczynska-Cedro, K., Winek, D., and Ceremuzynski, L. Effects of oral L-arginine supplementation on exercise-induced QT dispersion and exercise tolerance in stable angina pectoris. Int.J Cardiol 9-15-2000;75(2-3):205-210. View abstract.
  72. Sozykin, A. V., Noeva, E. A., Balakhonova, T. V., Pogorelova, O. A., and Men'shikov, M. I. [Effect of L-arginine on platelet aggregation, endothelial function adn exercise tolerance in patients with stable angina pectoris]. Ter.Arkh. 2000;72:24-27. View abstract.
  73. Maxwell, A. J., Anderson, B. E., and Cooke, J. P. Nutritional therapy for peripheral arterial disease: a double-blind, placebo-controlled, randomized trial of HeartBar. Vasc.Med. 2000;5:11-19. View abstract.
  74. Cartledge, J. J., Davies, A. M., and Eardley, I. A randomized double-blind placebo-controlled crossover trial of the efficacy of L-arginine in the treatment of interstitial cystitis. BJU.Int. 2000;85:421-426. View abstract.
  75. Komers, R., Komersova, K., Kazdova, L., Ruzickova, J., and Pelikanova, T. Effect of ACE inhibition and angiotensin AT1 receptor blockade on renal and blood pressure response to L-arginine in humans. J Hypertens. 2000;18:51-59. View abstract.
  76. Beale, R. J., Bryg, D. J., and Bihari, D. J. Immunonutrition in the critically ill: a systematic review of clinical outcome. Crit Care Med. 1999;27:2799-2805. View abstract.
  77. de Gouw, H. W., Verbruggen, M. B., Twiss, I. M., and Sterk, P. J. Effect of oral L-arginine on airway hyperresponsiveness to histamine in asthma. Thorax 1999;54:1033-1035. View abstract.
  78. Facchinetti, F., Longo, M., Piccinini, F., Neri, I., and Volpe, A. L-arginine infusion reduces blood pressure in preeclamptic women through nitric oxide release. J Soc Gynecol.Investig. 1999;6:202-207. View abstract.
  79. De, Nicola L., Bellizzi, V., Minutolo, R., Andreucci, M., Capuano, A., Garibotto, G., Corso, G., Andreucci, V. E., and Cianciaruso, B. Randomized, double-blind, placebo-controlled study of arginine supplementation in chronic renal failure. Kidney Int. 1999;56:674-684. View abstract.
  80. Kobayashi, N., Nakamura, M., and Hiramori, K. Effects of infusion of L-arginine on exercise-induced myocardial ischemic ST-segment changes and capacity to exercise of patients with stable angina pectoris. Coron.Artery Dis 1999;10:321-326. View abstract.
  81. Battaglia, C., Salvatori, M., Maxia, N., Petraglia, F., Facchinetti, F., and Volpe, A. Adjuvant L-arginine treatment for in-vitro fertilization in poor responder patients. Hum.Reprod. 1999;14:1690-1697. View abstract.
  82. Wallace, A. W., Ratcliffe, M. B., Galindez, D., and Kong, J. S. L-arginine infusion dilates coronary vasculature in patients undergoing coronary bypass surgery. Anesthesiology 1999;90:1577-1586. View abstract.
  83. Debats IB, Booi DI, Wehrens KM, et al. Oral arginine supplementation and the effect on skin graft donor sites: a randomized clinical pilot study. J Burn Care Res. 2009 May-Jun;30:417-26. View abstract.
  84. Higashi Y, Oshima T, Sasaki S, et. al. Angiotensin-converting enzyme inhibition, but not calcium antagonism, improves a response of the renal vasculature to L-arginine in patients with essential hypertension. Hypertension. 1998 Jul;32:16-24. View abstract.
  85. Mercimek-Mahmutoglu S, Stöckler-Ipsiroglu S, Salomons GS. Creatine Deficiency Syndromes. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2014. View abstract.
  86. Anon. Arginine hydrochloride injection (marketed as R-Gene 10). FDA Drug Safety Newsletter 2009;2:16-18. Available at:
  87. Jude EB, Boulton AJ, Ferguson MW, Appleton I. The role of nitric oxide synthase isoforms and arginase in the pathogenesis of diabetic foot ulcers: possible modulatory effects by transforming growth factor beta 1. Diabetologia 1999;42:748-57. View abstract.
  88. Arana V, Paz Y, González A, Méndez V, Méndez JD. Healing of diabetic foot ulcers in L-arginine-treated patients. Biomed Pharmacother 2004;58:588-97. View abstract.
  89. Fossel ET. Improvement of temperature and flow in feet of subjects with diabetes with use of a transdermal preparation of L-arginine: a pilot study. Diabetes Care 2004;27:284-5. View abstract.
  90. Chauhan A, More RS, Mullins PA, et al. Aging-associated endothelial dysfunction in humans is reversed by L-arginine. J Am Coll Cardiol 1996;28:1796-804. View abstract.
  91. Bednarz B, Jaxa-Chamiec T, Maciejewski P, et al. Efficacy and safety of oral l-arginine in acute myocardial infarction. Results of the multicenter, randomized, double-blind, placebo-controlled ARAMI pilot trial. Kardiol Pol 2005;62:421-7. View abstract.
  92. Schulman SP, Becker LC, Kass DA, et al. L-arginine therapy in acute myocardial infarction. The vascular interaction with age in myocardial infarction (VINTAGE MI) randomized clinical trial. JAMA 2006;295:58-64. View abstract.
  93. Resnick DJ, Softness B, Murphy AR, et al. Case report of an anaphylactoid reaction to arginine. Ann Allergy Asthma Immunol 2002;88:67-8. View abstract.
  94. Staff AC, Berge L, Haugen G, et al. Dietary supplementation with L-arginine or placebo in women with pre-eclampsia. Acta Obstet Gynecol Scand 2004;83:103-7. View abstract.
  95. Morris CR, Morris SM Jr, Hagar W, et al. Arginine therapy: a new treatment for pulmonary hypertension in sickle cell disease? Am J Respir Crit Care Med 2003;168:63-9. View abstract.
  96. Venho B, Voutilainen S, Valkonen VP, et al. Arginine intake, blood pressure, and the incidence of acute coronary events in men: the Kuopio Ischaemic Heart Disease Risk Factor Study. Am J Clin Nutr 2002;76:359-64.. View abstract.
  97. Huynh NT, Tayek JA. Oral arginine reduces systemic blood pressure in type 2 diabetes: its potential role in nitric oxide generation. J Am Coll Nutr 2002;21:422-7.. View abstract.
  98. Stanislavov R, Nikolova V. Treatment of erectile dysfunction with pycnogenol and L-arginine. J Sex Marital Ther 2003;29:207-13.. View abstract.
  99. de Luis DA, Izaola O, Cuellar L, et al. Effect of c-reactive protein and interleukins blood levels in postsurgery arginine-enhanced enteral nutrition in head and neck cancer patients. Eur J Clin Nutr 2003;57:96-9. View abstract.
  100. Parker JO, Parker JD, Caldwell RW, et al. The effect of supplemental L-arginine on tolerance development during continuous transdermal nitroglycerin therapy. J Am Coll Cardiol 2002;39:1199-203. View abstract.
  101. Amin HJ, Zamora SA, McMillan DD, et al. Arginine supplementation prevents necrotizing enterocolitis in the premature infant. J Pediatr 2002;140:425-31. View abstract.
  102. Ohtsuka Y, Nakaya J. Effect of oral administration of L-arginine on senile dementia. Am J Med 2000;108:439. View abstract.
  103. Houghton JL, Philbin EF, Strogatz DS, et al. The presence of African American race predicts improvement in coronary endothelial function after supplementary L-arginine. J Am Coll Cardiol 2002;39:1314-22. View abstract.
  104. Bocchi EA, Vilella de Moraes AV, Esteves-Filho A, et al. L-arginine reduces heart rate and improves hemodynamics in severe congestive heart failure. Clin Cardiol 2000;23:205-10. View abstract.
  105. Katz SD, Khan T, Zeballos GA, et al. Decreased activity of the L-arginine-nitric oxide metabolic pathway in patients with congestive heart failure. Circulation 1999;99:2113-7. View abstract.
  106. Wallace AW, Tom WL. Interaction of L-arginine and phosphodiesterase inhibitors in vasodilation of the porcine internal mammary artery. Anesth Analg 2000;90:840-6. View abstract.
  107. Chin-Dusting JP, Kaye DM, Lefkovits J, et al. Dietary supplementation with L-arginine fails to restore endothelial function in forearm resistance arteries of patients with severe heart failure. J Am Coll Cardiol 1996;27:1207-13. View abstract.
  108. Cheng JW, Balwin SN. L-arginine in the management of cardiovascular diseases. Ann Pharmacother 2001;35:755-64. View abstract.
  109. Mullen MJ, Wright D, Donald AE, et al. Atorvastatin but not L-arginine improves endothelial function in type I diabetes mellitus: a double-blind study. J Am Coll Cardiol 2000;36:410-6. View abstract.
  110. Wu G, Meininger CJ. Arginine nutrition and cardiovascular function. J Nutr 2000;130:2626-9. View abstract.
  111. Tepaske R, Velthuis H, Oudemans-van Straaten HM, et al. Effect of preoperative oral immune-enhancing nutritional supplement on patients at high risk of infection after cardiac surgery: a randomised placebo-controlled trial. Lancet 2001;358:696-701. View abstract.
  112. Siani A, Pagano E, Iacone R, et al. Blood pressure and metabolic changes during dietary L-arginine supplementation in humans. Am J Hypertens 2000;13:547-51. View abstract.
  113. Blum A, Hathaway L, Mincemoyer R, et al. Oral L-arginine in patients with coronary artery disease on medical management. Circulation 2000;101:2160-4. View abstract.
  114. Ceremuzynski L, Chamiec T, Herbaczynska-Cedro K. Effect of supplemental oral L-arginine on exercise capacity in patients with stable angina pectoris. Am J Cardiol 1997;80:331-3. View abstract.
  115. Maxwell AJ, Zapien MP, Pearce GL, et al. Randomized trial of a medical food for the dietary management of chronic, stable angina. J Am Coll Cardiol 2002;39:37-45. View abstract.
  116. Park KG. The immunological and metabolic effects of L-arginine in human cancer. Proc Nutr Soc 1993;52:387-401. View abstract.
  117. Kanaya Y, Nakamura M, Kobayashi N, Hiramori K. Effects of L-arginine on lower limb vasodilator reserve and exercise capacity in patients with chronic heart failure. Heart 1999;81:512-7. View abstract.
  118. Feskens EJM, Oomen CM, Hogendoorn E, et al. Arginine intake and 25-year CHD mortality: the seven countries study (letter). Eur Heart J 2001;22:611-2. View abstract.
  119. Hambrecht R, Hilbrich L, Erbs S, et al. Correction of endothelial dysfunction in chronic heart failure: additional effects of exercise training and oral L-arginine supplementation. J Am Coll Cardiol 2000;35:706-13. View abstract.
  120. Kemen M, Senkal M, Homann HH, et al. Early postoperative enteral nutrition with arginine-omega-3 fatty acids and ribonucleic acid-supplemented diet vs placebo in cancer patients: an immunologic evaluation of impact. Crit Care Med 1995;23:652-9. View abstract.
  121. Senkal M, Kemen M, Homann HH, et al. Modulation of postoperative immune response by enteral nutrition with a diet enriched with arginine, RNA, and omega-3 fatty acids in patients with upper gastrointestinal cancer. Eur J Surg 1995;161:115-22. View abstract.
  122. Daly JM, Lieberman MD, Goldfine J, et al. Enteral nutrition with supplemental arginine, RNA, and omega-3 fatty acids in patients after operation: immunologic, metabolic and clinical outcome. Surgery 1992;112:56-67. View abstract.
  123. Watanabe G, Tomiyama H, Doba N. Effects of oral administration of L-arginine on renal function in patients with heart failure. J Hypertens 2000;18:229-34. View abstract.
  124. Rector TS, Bank AJ, Mullen KA, et al. Randomized, double-blind, placebo-controlled study of supplemental oral L-arginine in patients with heart failure. Circulation 1996;93:2135-41. View abstract.
  125. Blum A, Porat R, Rosenschein U, et al. Clinical and inflammatory effects of dietary L-arginine in patients with intractable angina pectoris. Am J Cardiol 1999;15:1488-90. View abstract.
  126. Boger RH, Bode-Boger SM, Thiele W, et al. Restoring vascular nitric oxide formation by L-arginine improves the symptoms of intermittent claudication in patients with peripheral arterial occlusive disease. J Am Coll Cardiol 1998;32:1336-44. View abstract.
  127. Korting GE, Smith SD, Wheeler MA, et al. A randomized double-blind trial of oral L-arginine for treatment of interstitial cystitis. J Urol 1999;161:558-65. View abstract.
  128. Oomen CM, van Erk MJ, Feskens E, et al. Arginine intake and risk of coronary heart disease mortality in elderly men. Arterioscler Thromb Vasc Biol 2000;20:2134-9. View abstract.
  129. Brittenden J, Park KGM, Heys SD, et al. L-Arginine stimulates host defenses in patients with breast cancer. Surgery 1994;115:205-12. View abstract.
  130. Tenenbaum A, Fisman EZ, Motro M. L-arginine: Rediscovery in progress. Cardiology 1998;90:153-9. View abstract.
  131. Wang R, Ghahary A, Shen YJ, et al. Human dermal fibroblasts produce nitric oxide and express both constitutive and inducible nitric oxide synthase isoforms. J Invest Dermatol 1996;106:419-27. View abstract.
  132. Peters H, Noble NA. Dietary L-arginine in renal disease. Semin Nephrol 1996;16:567-75. View abstract.
  133. Klotz T, Mathers MJ, Braun M, et al. Effectiveness of oral L-arginine in first-line treatment of erectile dysfunction in a controlled crossover study. Urol Int 1999;63:220-3. View abstract.
  134. Clark RH, Feleke G, Din M, et al. Nutritional treatment for acquired immunodeficiency virus-associated wasting using beta-hydroxy beta-methylbutyrate, glutamine, and arginine: a randomized, double-blind, placebo-controlled study. JPEN J Parenter Enteral Nutr 2000;24:133-9. View abstract.
  135. FDA. List of orphan designations and approvals. Office of Orphan Products Development. Available at:
  136. Clarkson P, Adams MR, Powe AJ, et al. Oral L-arginine improves endothelium-dependent dilation in hypercholesterolemic young adults. J Clin Invest 1996;97:1989-94. View abstract.
  137. Creager MA, Gallagher SJ, Girerd XJ, et al. L-arginine improves endothelium-dependent vasodilation in hypercholesterolemic humans. J Clin Invest 1992;90:1248-53. View abstract.
  138. Chen J, Wollman Y, Chernichovsky T, et al. Effect of oral administration of high-dose nitric oxide donor L-arginine in men with organic erectile dysfunction: results of a double-blind, randomized, placebo-controlled study. BJU Int 1999;83:269-73. View abstract.
  139. Saijyo T, Nomura M, Nakaya Y, Saito K, et al. Autonomic nervous system activity during infusion of L-arginine in patients with liver cirrhosis. Liver 1998;18:27-31. View abstract.
  140. Sapienza MA, Kharitonov SA, Horvath I, et al. Effect of inhaled L-arginine on exhaled nitric oxide in normal and asthmatic subjects. Thorax 1998;53:172-5. View abstract.
  141. Griffith RS, DeLong DC, Nelson JD. Relation of arginine-lysine antagonism to herpes simplex growth in tissue culture. Chemotherapy 1981;27:209-13. View abstract.
  142. Hibbard MK, Sandri-Goldin, RM. Arginine-rich regions succeeding the nuclear localization region of the herpes simplex virus type 1 regulatory protein ICP27 are required for efficient nuclear localization and late gene expression. J Virol 1995;69:4656-7. View abstract.
  143. Takano H, Lim HB, Miyabara Y, et al. Oral administration of L-arginine potentiates allergen-induced airway inflammation and expression of interleukin-5 in mice. J Pharmacol Exp Ther 1998;286:767-71. View abstract.
  144. Adams MR, McCredie R, Jessup W, et al. Oral L-arginine improves endothelium-dependent dilatation and reduces monocyte adhesion to endothelial cells in young men with coronary artery disease. Atherosclerosis 1997;129:261-9. View abstract.
  145. Wheeler MA, Smith SD, Saito N, et al. Effect of long-term oral L-arginine on the nitric oxide synthase pathway in the urine from patients with interstitial cystitis. J Urol 1997;158:2045-50. View abstract.
  146. Pichard C, Sudre P, Karsegard V, et al. A randomized double-blind controlled study of 6 months of oral nutritional supplementation with arginine and omega-3 fatty acids in HIV-infected patients. Swiss HIV Cohort Study. AIDS 1998;12:53-63. View abstract.
  147. Andres A, Morales JM, Praga M, et al. L-arginine reverses the antinatriuretic effect of cyclosporin in renal transplant patients. Nephrol Dial Transplant 1997;12:1437-40. View abstract.
  148. Lerman A, Burnett JC Jr, Higano ST, et al. Long-term L-arginine improves small-vessel coronary endothelial function in humans. Circulation 1998;97:2123-8. View abstract.
  149. Sandrini G, Franchini S, Lanfranchi S, et al. Effectiveness of ibuprofen-arginine in the treatment of acute migraine attacks. Int J Clin Pharmacol Res 1998;18:145-50. View abstract.
  150. Bode-Boger SM, Boger RH, Galland A, et al. L-arginine-induced vasodilation in healthy humans: pharmacokinetic-pharmacodynamic relationship. Br J Clin Pharmacol 1998;46:489-97. View abstract.
  151. Ehren I, Lundberg JO, Adolfsson J, Wiklund NP. Effects of L-arginine treatment on symptoms and bladder nitric oxide levels in patients with interstitial cystitis. Urology 1998;52:1026-9. View abstract.
  152. McKevoy GK, ed. AHFS Drug Information. Bethesda, MD: American Society of Health-System Pharmacists, 1998.
Show more references
Show fewer references
Last reviewed - 12/03/2014

Page last updated: 10 December 2014